Full-Time
Generative AI platform for life-science collaboration
No salary listed
Lehi, UT, USA
Hybrid
Hybrid role based at the Lehi headquarters.
See people who can refer or advise you
Weave.bio provides a platform for life sciences collaboration by integrating a generative AI system with a knowledge graph to connect researchers, data, and projects. The platform generates insights and maps connections across datasets, research teams, and workflows, while an incentive system rewards contributors proportionally to the value they add. Unlike tools that focus on a single function, Weave.bio combines collaboration features with a data-linking graph and an explicit rewards model to reduce silos and encourage sharing. The goal is to accelerate biomedical research and development, helping pharma, biotech, and academic researchers move from discovery toward real-world impact faster.
Company Size
51-200
Company Stage
Series A
Total Funding
$31.6M
Headquarters
New Haven, Connecticut
Founded
2023
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Professional Development Budget
Weave Bio, an AI-powered regulatory automation platform for drug development, has launched global submission capabilities allowing pharmaceutical teams to manage all regulatory filings from a single source of truth. The new features enable companies to use one verified reference set across multiple jurisdictions, from initial Investigational New Drug applications through to final approval. The platform includes a pre-loaded EU Clinical Trial Application template compliant with European Medicines Agency standards, plus a custom template builder for other jurisdictions. This eliminates the traditional need to rebuild dossiers from scratch for each new market. Founded in 2022 and based in San Francisco, Weave Bio is backed by investors including USVP, Innovation Endeavors and Magnetic Ventures. The company will demonstrate the new capabilities at the DIA 2026 Annual Meeting in Philadelphia.
Syner-G launches 3D Intelligence (3Di(TM), a people-centered AI transformation service for biopharma. Jun 02, 2026, 09:55 ET Syner-G launches 3D Intelligence (3Di(TM), an enterprise AI transformation service for biopharma that combines human-centered strategy, regulatory expertise, and scalable implementation to move organizations from fragmented AI pilots to measurable, enterprise-wide impact. BOSTON, June 2, 2026 /PRNewswire-PRWeb/ - Syner-G, a Strategic Development & Delivery Partner(TM) to biopharma innovators, today announced the official launch of 3D Intelligence (3Di(TM), an enterprise AI transformation service designed to move organizations from fragmented experimentation to scaled, measurable impact. Designed for regulated environments, 3Di applies a human-centered, strategy-led approach to deliver fit-for-purpose AI solutions that scale while preserving human judgment. The approach reflects key principles from FDA and EMA guidance, emphasizing human ownership in work design and decision-making, alongside risk-based practices, transparency, and disciplined lifecycle and data management. Since October 2025, Syner-G has piloted 3Di with sponsor organizations across product development, portfolio management, and regulatory authoring, alongside an internal transformation of its own Medical Writing business. As part of this internal effort, Syner-G has partnered with Weave Bio as its technology provider for AI-augmented authoring and knowledge management across the IND-to-NDA lifecycle. Early results demonstrate significant reductions in authoring time across a range of submission documents, without compromising quality or accuracy. Full pilot data to be published within the coming months. "Partnering with Syner-G shows how AI delivers real, measurable impact when it's implemented in a human-centered framework," said Brandon Rice, CEO of Weave Bio. "Together, we're driving measurable gains in speed, quality, and consistency for sponsors, while ensuring the technology strengthens the expertise behind it." "The real opportunity with AI isn't replacing work - it's elevating it," said Jennifer Kilroy, PhD, MBA, SVP of Strategy and Transformation at Syner-G. "But that only happens when organizations lead with empathy, are committed to building real trust, and stay anchored in the problems that are worth solving. As one of our AI advisors says, organizations must move at the speed of trust - and that's not a technology challenge, it's a human one. With 3Di, we're helping companies prepare their people, systems, and businesses to do exactly that." Rethinking the starting point for successful AI adoption While adoption is accelerating across biopharma, many organizations remain constrained by fragmented pilots, unclear governance, integration gaps, and low workforce adoption. 3Di addresses this by aligning AI initiatives to business and scientific priorities, focusing on high-impact use cases, and building the foundations needed to scale by integrating best practices in digital transformation, business excellence, and organizational change management. "3Di was built to help life sciences leaders answer the fundamental question every organization is facing: how do we apply AI in meaningful, scalable ways," said Ron Kraus, CEO of Syner-G. "By combining deep domain expertise, practical business cases, and human-centered AI implementation, we help clients identify high-impact opportunities, reduce execution risk, and deliver measurable outcomes across the drug development continuum. Our collaboration with Weave demonstrates how the right combination of AI capabilities and domain expertise can accelerate execution, improve decision-making, and ultimately help bring therapies to patients more efficiently." Upcoming engagements * June 10, 2026 (Virtual) - American Medical Writer's Association (AMWA) Webinar: "The Future of Medical Writing: Applying AI Through a Human-Centric Lens," 1-2 PM ET * June 22-25, 2026 (San Diego) - BIO International Convention: California Pavilion alongside Biocom and CLSA, Booth #1525 * June 23, 2026 (San Diego) - BLPN BIO Week Summit: Jennifer Kilroy, PhD, MBA to speak alongside leaders from Connect and AAIH on AI's role in transforming healthcare delivery * October 28, 2026 (Boston) - AI in Drug Discovery (AIDD) Summit: Syner-G to host a panel on advancing AI deployment in process development and manufacturing About Syner-G Syner-G is a Strategic Development & Delivery Partner(TM) to biopharma innovators, bringing together integrated scientific, regulatory, technical, and transformation consulting expertise across the development lifecycle. With more than 400 professionals across North America, Europe, and APAC, Syner-G collaborates closely with clients to reduce risk, accelerate development, and navigate the complexity of bringing therapies to market. Media Contact Lyndsey Brumbach, Syner-G, 1 909-921-2824, [email protected], synergbiopharma.com SOURCE Syner-G
Weave Bio has launched New Drug Application (NDA) workflow support on its AI-native regulatory automation platform, developed in partnership with Parexel. The platform now covers the full regulatory lifecycle for drug development. Through Parexel's real-world use of the platform for NDA submissions, Weave has delivered authoring timelines more than 60% faster than traditional methods. The platform uses AI-native data extraction, document authoring, content verification and workflow automation to streamline the NDA preparation process. Parexel, which brings over 40 years of regulatory experience, served as a strategic design partner and will maintain exclusive access as the only contract research organisation using the co-developed templates. Founded in 2022 and based in San Francisco, Weave Bio is backed by investors including USVP and Innovation Endeavors.
Weave Bio, an AI-driven regulatory automation company, has established its inaugural Strategic Advisory Board to guide the development of its platform and advance AI adoption in life sciences regulation. The board comprises senior executives from pharmaceutical companies and academia, including leaders from Takeda, Boehringer Ingelheim, Gilead, Stanford University and Serrado Capital. The SAB formation follows significant momentum for the San Francisco-based startup, which raised $20 million in Series A funding in October 2025 and announced a strategic partnership with Parexel. Weave Bio's platform streamlines regulatory content preparation for pharmaceutical companies, reducing regulatory timelines by over 50 percent whilst maintaining FDA and EMA compliance standards. Founded in 2022, Weave Bio has raised backing from investors including USVP, Innovation Endeavors and Magnetic Ventures.
Weave Bio raises $20M Series A to expand its AI-native platform that accelerates regulatory workflows for drug development.